Compare PAVS & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAVS | CTMX |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3M | 596.2M |
| IPO Year | 2019 | 2015 |
| Metric | PAVS | CTMX |
|---|---|---|
| Price | $1.28 | $5.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.86 |
| AVG Volume (30 Days) | 1.3M | ★ 3.7M |
| Earning Date | 08-04-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.22 |
| EPS | N/A | ★ 0.24 |
| Revenue | $12,416,127.00 | ★ $113,631,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $23.67 |
| Revenue Growth | ★ 18037.91 | N/A |
| 52 Week Low | $1.08 | $0.40 |
| 52 Week High | $150.00 | $6.35 |
| Indicator | PAVS | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.53 |
| Support Level | N/A | $5.17 |
| Resistance Level | N/A | $6.35 |
| Average True Range (ATR) | 0.00 | 0.50 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 0.00 | 29.01 |
Paranovus Entertainment Technology Ltd, through its subsidiaries, is involved in the AI-powered entertainment industry, to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It has entered into a software development agreement for the development of 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic. The group is also involved in an e-commerce business and provides TikTok-related e-commerce solutions for customers.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.